NEWS & MEDIA

Elevaris is helping medical device companies speed up R&D with its XLerator live prototyping program—cutting weeks of design work down to just days through hands-on, in-factory collaboration.

In light of the April 2 announcement regarding new tariffs on U.S. global trading partners, we want to assure you that we are diligently analyzing the effect of these tariffs on our supply chain.

We wanted to provide our customers more details on our adoption of the Elevaris brand and what it means for operations going forward. In approaching this process, we had a goal of rebranding with as little disruption to our customers as possible.

Our rebrand is another significant milestone in our journey together since Spectra acquired XLPT in September 2024. It’s our promise to leverage the strengths of our individual brands while emphasizing our singular commitment to you.

Spectra Medical Devices (Spectra) and XL Precision Technologies (XLPT) announced today their newly combined brand presence as Elevaris Medical Devices, a world-class Contract Development and Manufacturing Organization (CDMO) leveraging a proven legacy of excellence to usher in a new era of precision medical device development and manufacturing capabilities.

Spectra Medical Devices, LLC (“Spectra”), a portfolio company of QHP Capital, is pleased to announce the closing of its acquisition of XLPrecision Technologies Ltd. (“XL-PT”). XL-PT is now a wholly-owned subsidiary of Spectra.

Spectra Medical Devices, a global manufacturer of made-to-spec procedural needles and a distributor of complementary medical instruments, supplies, and pharmaceuticals, today announced that it has secured European Union Medical Device Regulation (EU MDR) certification for its entire range of radiofrequency (RF) needles.